DadFinStart your free weekAkebia Therapeutics, Inc. (AKBA) stock score
$0.80 ▼ -1.71% today
Akebia Therapeutics, Inc. (AKBA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 87.9 out of 100 on the Dad Score, a strong reading that places the business ahead of 88% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #111 of 974. Its strongest axes are valuation, quality and growth; its weakest are price action and risk.
Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →
The eight axes
Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.
Key numbers
What subscribers see on AKBA
- Value Score: is the price right for this business, the score the Value book is selected on.
- Trader Score: is it set up to move, refreshed every 15 minutes in the session.
- The full eight-axis breakdown, every input and its percentile.
- SEC filings, insider buying, earnings history and peers side by side.
- Whether it is in this week's published books, with the receipts.
Drug Manufacturers - Specialty & Generic peers
| Stock | Company | Dad Score | Band |
|---|---|---|---|
| TAK | Takeda Pharmaceutical Company Limi | 32.9 | weak |
| TEVA | Teva Pharmaceutical Industries Lim | 93.6 | strong |
| HLN | Haleon plc | 64.5 | middling |
| ZTS | Zoetis Inc. | 61.2 | middling |
| UTHR | United Therapeutics Corporation | 99.8 | strong |
| VTRS | Viatris Inc. | 54.4 | middling |
| NBIX | Neurocrine Biosciences, Inc. | 98.4 | strong |
| ELAN | Elanco Animal Health Incorporated | 84.0 | good |
Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.